| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 31st December 2020 | Paul Edward Walker | 222 | Open or private sale | $141.28 | $31,364.65 |
| 31st December 2020 | David M Mott | 2,158 | Grant/award etc. | $10.86 | $23,435.88 |
| 31st December 2020 | Paul Edward Walker | 1,499 | Open or private sale | $139.88 | $209,684.92 |
| 31st December 2020 | Paul Edward Walker | 33,302 | Open or private sale | $140.48 | $4,678,328.23 |
| 30th December 2020 | Paul Edward Walker | 7,144 | Open or private sale | $143.07 | $1,022,056.36 |
| 30th December 2020 | Paul Edward Walker | 25,109 | Open or private sale | $141.78 | $3,559,883.71 |
| 30th December 2020 | Paul Edward Walker | 34,931 | Open or private sale | $141.31 | $4,936,190.43 |
| 30th December 2020 | Peter J Barris | 5,229 | Grant/award etc. | $0.00 | |
| 30th December 2020 | Paul Edward Walker | 1,208 | Open or private sale | $143.81 | $173,722.24 |
| 14th December 2020 | David M Mott | 486 | Other acquisition or disposition | $0.00 |
Regulus Therapeutics
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Regulus Therapeutics, Inc. is a biopharmaceutical company. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. The company is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases.
Ticker: RGLS
Sector: Health Technology
Industry: Pharmaceuticals: Other
SEC Central Index Key (CIK): 1505512
Employees: 21
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $23 M (0%)
Other Assets, Current: $573 Th (-53%)
Assets, Current: $29 M (-29%)
Property, Plant and Equipment, Net: $684 Th (-25%)
Other Assets, Noncurrent: $387 Th (-20%)
Assets: $30 M (-29%)
Accounts Payable, Current: $1 M (-22%)
Accrued Liabilities, Current: $1 M (17%)
Liabilities, Current: $21 M (-2%)
Other Liabilities, Noncurrent: $217 Th (-53%)
Liabilities: $21 M (-3%)
Common Stock, Value, Issued: $36 Th (71%)
Common Stock, Shares, Issued: $36 M (70%)
Additional Paid in Capital, Common Stock: $433 M (0%)
Retained Earnings (Accumulated Deficit): $424 M (3%)
Stockholders' Equity (Parent): $9 M (0%)
Liabilities and Equity: $30 M (-29%)
Research and Development: $4 M (-42%)
General and Administrative Expenses: $2 M (-51%)
Operating Income/Loss: $6 M (-46%)
Provision for income taxes: $0 (-100%)
News
DXP Enterprises Reports Third Quarter 2020 Results
6th November 2020
17 Arrested For Running Fake Call Centre In Delhi: Police
6th November 2020
Ubiquiti Inc. Reports First Quarter Fiscal 2021 Financial Results
6th November 2020
